News

Get the latest on MHICC through recent headlines, feature stories and news. Stay up-to-date on the latest news and information from MHICC.

Montreal Health Innovations Coordinating Center (MHICC) Selects Montrium’s eQMS to Enhance its Operational Excellence
September 25 2024

Montreal, QC –The Montreal Health Innovations Coordinating Center (MHICC), a premier full-service academic Contract Research Organization, is delighted to announce its selection of Montrium’s electronic Quality Management Software (eQMS). This tool will help manage quality records more efficiently, and thus improve compliance and quality for clinical trials initiated by investigators and sponsors in the medical devices, pharmaceuticals and biotechnology fields.

"The MHICC has undergone significant transformation in recent years, and the integration of the eQMS marks a key milestone in its evolution,” , said Sophie Tanguay, Executive Director at the MHICC. “We’re excited to launch the eQMS. This advancement highlights our commitment to continuous improvement and strengthens our operations.”

This strategic decision aims to optimize the MHICC’s Phase I to IV clinical trials that span across multiple fields, including cardiology, precision medicine, endocrinology, pharmacogenomics, and oncology, while offering decentralized trial options. The implementation of the eQMS will support the clinical trial operations with robust, integrated solutions designed to streamline processes.

For more information: www.mhicc.org

Leading ECM Platform for Life Science Organizations | Montrium

LinkedIn MHICC

MHICC Integrates LifeSphere® Safety to leverage Generative AI and LLM Technologies
July 16, 2024

LifeSphere® was developed by ArisGlobal, a technology company at the forefront of the life sciences domain.
Montreal, QC — The Montreal Health Innovations Coordinating Center (MHICC) announces the integration of the LifeSphere® Safety Database platform by ArisGlobal. It’s designed to enhance the MHICC’s clinical and drug safety management, reporting, and pharmacovigilance capabilities. The MultiVigilance and Reporting & Analytics features utilize cutting-edge technologies, including next-generation AI.

“We’re excited to equip our Medical experts with a powerful tool to enhance the speed and accuracy of safety management, reporting, and medical writing”, states Sophie Tanguay, Executive Director at the MHICC. “This automation benefits both sites and sponsors in its safety workflows and actions.”

LifeSphere’s Safety Database is a comprehensive technology platform that optimizes global collaboration while ensuring compliance. This technology provides an end-to-end safety process that includes case creation, case processing, periodic and comprehensive reporting, and detailed analytics.
The MHICC’s Medical Monitoring and Safety team serves small to large organizations at every stage of clinical development, from early phase to post-marketing. We combine cutting-edge technology with a dedicated team to deliver high-quality, rapid services with a customer-centered approach. Our offerings include clinical safety management, pharmacovigilance, regulatory compliance, and medical writing.

For more information, please contact Axel Bergman, Dir, Business Development:
axel.bergman@mhicc.org

LifeSphere | Life Sciences R&D Software Platform

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
November 27, 2023

Dr. Jean-Claude Tardif, the principal investigator of the study and Director of the Research Center at the Montreal Heart Institute stated, "We are excited to explore the potential therapeutic benefits of avenanthramides and believe results from this study could mark a significant step forward in understanding the potential of avenanthramides in cardiovascular disease. Not only will the study assess safety of avenanthramides in healthy subjects, but it could also provide early signs of activity in subjects with low grade inflammation as part of the Phase 2a component. The results of such studies will provide valuable insights into the potential role of avenanthramides in reducing vascular inflammation and may have implications for cardiovascular health.”

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
December 22, 2022

Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received approval from Health Canada to initiate its Phase 1/2a study evaluating the safety, tolerability, bioavailabilty and efficacy of its pharmaceutical grade tablet of avenanthramide as a potential anti-inflammatory product.

The Montreal Heart Institute Receives $9.35 Million From the Quebec Government to Lead a Major Virtual Clinical Trial Project
December 13, 2021

The Montreal Heart Institute (MHI) announces that it has won a request for proposals from the Fonds d’accélération des collaborations en santé (FACS). Pierre Fitzgibbon, Minister of Economic and Innovation, announced today a $9.35 million grant from the Government of Quebec to develop and deploy the project entitled Paradigm Shift in the Conduct of Clinical Trials...

Fighting gut infections contributes to preventing Crohn’s disease and ulcerative colitis.
November 11, 2021

A research team from the Montreal Heart Institute (ICM) has shown that genes present in specific intestinal cells protect against the development of inflammatory bowel diseases (IBD). Published today in the scientific journal Genome Medicine, the study results show that more than a dozen of these genes, which contribute to the development of Crohn’s disease and ulcerative colitis, help fight viral and bacterial infections ...

A new world-class hub for clinical research and precision medicine
October 26, 2021

Reaching nearly $17.5 million, this initiative launched as part of the first FACS program call for proposals is supported by the Ministry of Economy and Innovation (MEI) with a $6.45 million grant and is co-funded by private partners, including Quebec-based DalCor Pharmaceuticals, world-class biopharmas AstraZeneca, Bayer Inc. et Pharmascience as well as the Montreal Heart Institute Foundation...